Table 6. Univariate and multivariate cox regression analysis of RNF43, YAP expression classifier and clinical characteristicswith overall survival and progression-free survival in cohort 2.

Characteristics	Overall survival				Progression-free survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (<60 y vs. ≥60 y)	0.581 (0.202–1.676)	0.315			0.584 (0.203–1.683)	0.319
Gender (Male vs. Female)	1.24 (0.389–3.953)	0.716			1.281 (0.402–4.084)	0.676
WHO/ISUP Grading (1–2 vs. 3–4)	4.973 (1.558–15.872)	0.007	6.209 (1.53–25.195)	0.011	4.981 (1.56–15.902)	0.007	6.159 (1.451–26.142)	0.014
TNM stage (1–2 vs. 3–4)	14.479 (4.982–42.081)	<0.001	7.908 (2.394–21.255)	0.004	16.108 (5.524–46.968)	<0.001	8.655 (0.576–12.241)	0.002
SSIGN (1–4 vs. ≥5)	20.736 (7.168-59.982)	<0.001	11.821 (2.537–55.071)	0.002	24.440 (8.37–71.363)	<0.001	12.145(4.288–69.768)	0.001
RNF43 expression (Low vs High)	0.984 (0.976–0.993)	<0.001	0.991 (0.979–1.003)	0.002	0.984 (0.976–0.993)	<0.001	0.989 (0.977–1.002)	0.001
YAP expression (Low vs. High)	1.042 (0.999–1.087)	0.006	0.996 (0.935–1.062)	0.009	1.042 (0.999–1.088)	0.006	0.984 (0.922–1.049)	0.009